The Global Adherence Project (GAP): A multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

European Journal of Neurology

Volumn 18, Issue 1, 2011, Pages 69-77

  Devonshire, V ^a   Lapierre, Y ^b   Macdonell, R ^c   Ramo Tello, C ^d   Patti, F ^e   Fontoura, P ^f   Suchet, L ^g   Hyde, R ^h   Balla, I ^h   Frohman, E M ⁱ   Kieseier, B C ^j  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c AUSTIN HOSPITAL   (Australia)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^g Cabinet Medical   (France)

^h Biogen Idec International GmbH   (Switzerland)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

Adherence; Disease modifying therapy; Glatiramer acetate; Interferon; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; COGNITION; DISEASE DURATION; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SEX RATIO; TREATMENT DURATION;

FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 78650128757     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03110.x     Document Type: Article

References (27)

1. Sabaté E, ed. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization, 2003.
2. Mohr DC, Goodkin DE, Likosky W, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence in treatment. Mult Scler 1996; 2: 222-226.
3. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997; 54: 531-533.
4. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2001; 33: 231-239.
5. Mohr DC, Goodkin DE, Masuoka L, et al. Treatment adherence and patient retention in the first year of a phase-III clinical trial for the treatment of multiple sclerosis. Mult Scler 1999; 5: 192-197.
6. Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001; 23: 125-132.
7. Taus C, Taffi R, Morelli M, et al. Adherence to IFNβ therapy in multiple sclerosis: an Italian clinical setting [abstract]. Mult Scler 2001; 7: S55.
8. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs 2003; 35: 163-170.
9. Ruggieri RM, Settipani N, Viviano L, et al. Long-term interferon-β treatment for multiple sclerosis. Neurol Sci 2003; 24: 361-364.
10. Tremlett HL, Oger J. Interrupted therapy. Stopping and switching of the β-interferons prescribed for MS. Neurology 2003; 61: 551-554.
11. Berger BA, Hudmon KS, Liang H. Predicting treatment discontinuation among patients with multiple sclerosis: application of the transtheoretical model of change. J Am Pharm Assoc 2004; 44: 445-454.
12. Fraser C, Morgante L, Hadjimichael O, Vollmer T. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs 2004; 36: 120-129.
13. Berger BA, Liang H, Hudmon KS. Evaluation of software-based telephone counseling to enhance medication persistency among patients with multiple sclerosis. J Am Pharm Assoc 2005; 45: 466-472.
14. Daugherty KK, Butler JS, Mattingly M, Ryan M. Factors leading patients to discontinue multiple sclerosis therapies. J Am Pharm Assoc 2005; 45: 371-375.
15. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005; 11: 46-50.
16. Río J, Porcel J, Téllez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005; 11: 306-309.
17. Fiore APP, Fragoso YD. Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months. Arq Neuropsiquiatr 2005; 63: 738-740.
18. Treadaway KD, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in multiple sclerosis. J Neurol 2009; 256: 568-576.
19. Auquier P, Beresniak A, Fernandez O, et al. Validation of the multiple sclerosis international quality of life (MusiQoL) questionnaire [abstract]. Mult Scler 2005; 11(Suppl. 11): S92.
20. Benedict RHB, Munschauer F, Linn R, et al. Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler 2003; 9: 95-101.
21. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 1995; 45: 251-255.
22. Mohr DC, Likosky W, Boudewyn AC, et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 1998; 4: 487-489.
23. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41: 685-691.
24. Minden SL, Moes EJ, Orav J, Kaplan E, Reich P. Memory impairment in multiple sclerosis. J Clin Exp Neuropsychol 1990; 12: 566-586.
25. Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology 1996; 46: 628-632.
26. Holland N, Wiesel P, Cavallo P, et al. Adherence to disease-modifying therapy in multiple sclerosis: part I. Rehabil Nurs 2001; 26: 172-176.
27. Coppola G, Lanzillo R, Florio C, et al. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. Eur J Neurol 2006; 13: 1014-1021.